According to a release issued by Dr. Reddy's to the BSE today, the unit, with a built up area of 15.7 acre, is the seventh finished dosage facility of the company.
"The state-of-the-art plant is specially designed to manufacture a broad range of products including cytotoxic and anti-hormonal products and injectibles catering to the international market for the treatment of cancer, hormonal imbalances & other diseases," the release added.
"The new facility is benchmarked to the highest global regulatory standards, and is designed to cater to a global market that requires the most stringent standards of quality," Satish Reddy, managing director & CEO of Dr. Reddy's Labs, said.
The plant has a production capacity of 40 million cytotoxic OSD capsules, 40 million anti-hormonal formulations & seven million injectibles per annum, the release said.
